+ Phase-III-support-Carcinogenicity


We have long-held experience of conducting carcinogenicity studies in the pharmaceutical and chemical industry sectors; having undertaken them for more than 30 years.  Studies are run in our purpose built rodent facilities where technologists have well-honed skills in dosing over prolonged periods and in palpation of masses.

Pathology is critical for the successful outcome of these studies and we employ three full-time toxicological pathologists with combined experience amounting to over six decades, including extensive carcinogenicity study experience. The qualifications of our pathologists are detailed below:

  • Pathologist A: BDS(Edin) DipRCPath (Tox) FRCPath
  • Pathologist B: BSc PhD DipRCPath (Tox) FRCPath
  • Pathologist C: DVM MRCVS

Statistical analysis is overseen by one of the leading UK experts in this field.

Study Types

  • 2 year “lifetime” bioassays
  • Preliminary 3 month toxicity studies
  • rasH2 transgenic mouse model

Dose Routes

  • Dietary
  • Oral gavage
  • Sub-cutaneous
Our News & Events
MDC Connects Webinar 8: Is my Compound Safe?
1 June 2020
Join Sequani for the how to get your molecule in to humans webinar
Read More
Mice in Juvenile Toxicity Testing
26 November 2018
Mice in Juvenile Toxicity Testing
Read More
Biomarker Validation – Mountain, Molehill or Something in Between?
13 June 2018
Biomarker Validation – Mountain, Molehill or Something in Between?
Read More